Key result
The overall risk of cardiotoxicity with 5-fluorouracil and folinic acid was 3%, with a higher risk in patients with a history of cardiac disease.
Why the study?
Does the combination of 5-fluorouracil and folinic acid cause cardiotoxicity in patients with advanced gastrointestinal cancer?
Cohort (n=390)
Yes
Does the combination of 5-fluorouracil and folinic acid cause cardiotoxicity in patients with advanced gastrointestinal cancer?
The combination of 5-fluorouracil and folinic acid carries a 3% overall risk of cardiotoxicity, which is significantly elevated to 15.1% in patients with a prior history of cardiac disease.
Answers are grounded in this paper and cite their sources.
Prior cardiac disease may warrant closer 5-FU/folinic acid cardiotoxicity surveillance; observational data leave open causal inference and practice change.
BACKGROUND: Cardiotoxicity related to the widely used cytotoxic compound 5-fluorouracil (5-FU) is rare compared with the frequency observed with the use of anthracyclines. More effective protocols incorporating active biomodulatory compounds like folinic acid (FA) or combination chemotherapy change type and severity of toxicity as well. The objective of the current study was to assess cardiotoxicity of the combination 5-FU and folinic acid. METHODS: The authors' multicenter experience with 390 patients treated for advanced gastrointestinal cancer with intermediate-dose folinic acid and 5-FU was reviewed. RESULTS: The overall risk of cardiotoxicity was 3%, which is not significantly higher than that reported with 5-FU alone. Eight of 53 patients with a history of cardiac disease reported cardiac symptoms (15.1%), compared with 5 of 337 patients (1.5%) with a no history of cardiac disease. Median time to symptoms was 3 days (range, 2-6). Nine patients had symptoms resembling myocardial ischemia, one patient died due to assumed myocardial infarction related closely to fluorouracil treatment, four patients had supraventricular arrhythmia, and one patient had congestive heart failure. A history of cardiac disease was the only risk factor associated with cardiotoxicity. Relapses were frequent on reinstitution of therapy despite cardiac symptoms in the preceding cycle. Therapeutically or prophylactically administered nitrates had no significant effect. CONCLUSION: Physicians should be aware of the cardiotoxic properties of active fluorouracil treatment. The combination of 5-FU and leucovorin does not differ from single-agent therapy in frequency or type of cardiotoxicity. Close monitoring of patients is mandatory, especially for those patients at high risk for cardiac side effects. Treatment should be discontinued if coronary symptoms develop, because neither effective treatment nor prophylaxis exists for such symptoms.
No takes yet. Share an insight, caveat, or question.
Schöber et al. (1993) conducted a cohort in Advanced gastrointestinal cancer (n=390). 5-fluorouracil and folinic acid was evaluated on Cardiotoxicity. The overall risk of cardiotoxicity with 5-fluorouracil and folinic acid was 3%, with a higher risk in patients with a history of cardiac disease.
Synapse has enriched 10 related papers. Consider them for comparative context: